NCT06994520Enrolling by invitationPhase 2
Efficacy of Topical Cannabidiol for Eczema
Efficacy of Topical Cannabidiol in Patients With Eczema
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life. Chronic pruritic skin conditions such as atopic dermatitis, nummular eczema, lichen simplex chronicus, and prurigo nodularis are frequently observed. The pathogenesis of these conditions remains incompletely understood, and effective long-term treatment options are limited. Current therapies include topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, and systemic immunosuppressants. However, these treatments are often associated with adverse effects, and the diseases tend to follow a chronic, relapsing course. Therefore, the investigators aim to investigate the efficacy and safety of topical cannabis extract in patients with chronic pruritic skin conditions.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 18 May 2025
- Start date
- 1 May 2025
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Khon Kaen University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06994520
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 1 May 2025 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have taken oral steroids, immunosuppressive drugs, or received phototherapy within the past 3 months.
- Patients using other medications, particularly opioids or sedatives such as benzodiazepines.
Other illness
- Patients with chronic kidney disease, liver cirrhosis, cancer, or thyroid disease.
- Patients with a known allergy to cannabis-derived products, which may result from other ingredients and/or solvents used in the extraction process.
- Patients with severe or unstable cardio-pulmonary diseases (e.g., angina, peripheral vascular disease, cerebrovascular disease, or arrhythmia), or those at risk of cardiovascular disease.
- Patients with a history of psychosis, current active mood disorder, or anxiety disorder.
Lab values
- Patients taking medications known to potentially interact with cannabis extracts, such as warfarin, fluoroquinolones, or dihydropyridine calcium channel blockers.
Other
- Pregnant or breastfeeding women, or women planning to become pregnant.
- Patients who develop erythematous itchy rash in response to an open patch test using cannabis extract products.
- Patients who are addicted to substances, including nicotine, or are heavy alcohol users.
Who the study is looking for
- All participants must be aged 25 years or older.
- Patients must be diagnosed with eczema, including atopic dermatitis, nummular eczema, lichen simplex chronicus, or prurigo nodularis, with pruritus persisting for more than 6 weeks.
- Patients must be willing to refrain from using other topical products throughout the 4-week study period.
- Patients must provide written informed consent to participate in the study.
Age in the registry: 25 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Khon Kaen University Coordinator of this site? Confirm its status | Khon Kaen | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.